Clearside Biomedical is a biopharmaceutical company focused on revolutionizing treatment for sight-threatening back-of-the-eye diseases through its proprietary suprachoroidal space (SCS®) injection platform. The company’s patented SCS Microinjector® enables precise, in-office, non-surgical delivery of therapies directly to the macula, retina, or choroid — a targeted approach intended to improve vision outcomes. Clearside has brought the first suprachoroidally delivered therapy, XIPERE®, to market for macular edema associated with uveitis and is advancing its lead pipeline candidate, CLS-AX, a suprachoroidally administered axitinib injectable suspension, toward Phase 3 for neovascular age-related macular degeneration (wet AMD), with potential expansion into other retinal diseases.